Skip to main content

Paradigm Health

Category: AI in Healthcare

An AI-powered platform that accelerates clinical trial enrollment by matching patients with relevant studies and embedding research into routine healthcare workflows Paradigm Health was founded in 2022. The company is led by Kent Thoelke. Based in Columbus, OH, USA. Team size: 51-200. Total funding raised: $78M+. Latest round: Series B ($78M, Dec 2025) at flatiron acquisition. Key investors include ARCH Venture Partners, DFJ Growth, F-Prime Capital, General Catalyst, GV (Google Ventures), LUX Capital, Mubadala Capital, American Cancer Society's BrightEdge Fund.

Founded
2022
Headquarters
Columbus, OH, USA
Team size
51-200
Total funding
$78M+

Value proposition

Streamline and accelerate clinical trial enrollment, reduce administrative burdens for providers, help sponsors bring therapies to market faster, and make clinical trials accessible to any patient anywhere

Products and solutions

AI-powered clinical trial enrollment platform, Patient matching automation, Site feasibility assessment, Trial design services, Real-world evidence generation

Unique value

AI-native platform that combines EMR and genomic data for patient matching, embedded directly into routine care workflows, creating the largest oncology research network in the US with 70% of cancer population within reach

Target customer

Healthcare providers (hospitals, research sites, 166 provider organizations with 2,100 care locations) and biopharmaceutical companies/sponsors (15 of top 20 global pharma)

Industries served

Healthcare, Life Sciences, Clinical Research, Biotechnology, Oncology

Technology advantage

AI-enabled infrastructure that automates patient matching and site feasibility, integrates with 166 provider organizations across 45 states, processes unstructured medical records using LLMs, enables 4x faster trial accrual

How they differentiate

Paradigm Health differentiates through its AI-native platform embedded in routine care, largest oncology research network in US, focus on community and rural health systems, and acquisition of Flatiron Health's clinical research business combined with strategic partnership

Main competitors

Medable, Teckro, ConcertAI, IQVIA, ICON

Key partnerships

Roche/Flatiron Health (strategic partnership and acquisition), ARCH Venture Partners, Sheba Medical Center ARC Innovation, 15 of top 20 global pharmaceutical companies, 23 NCI-Designated Cancer Centers

Notable customers

Roche, Bristol Myers Squibb, 15 of the top 20 global pharmaceutical companies, 23 NCI-Designated Cancer Centers, 123 community oncology practices

Major milestones

Acquisition of Deep Lens, Partnerhship with Roche to advance AI-driven clinical trial enrollment, Acquisition of Flatiron Health's Clinical Research Business (December 2025), Creation of largest oncology research network in US, Raised $78M Series B in December 2025

Growth metrics

4x faster trial accrual for health systems, 166 provider organizations, 2,100 care locations, 70% of US cancer population within reach, 15 of top 20 global pharma companies as customers

Market positioning

Technology leader in clinical research space, positioned as the AI-native infrastructure built for modern clinical trials, creating patient-centric ecosystem

Geographic focus

United States (45 states, 2,100 care locations) with global expansion plans through partnerships like Sheba Medical Center

Patents and IP

Not publicly available

About Kent Thoelke

30+ year veteran of clinical research industry. Previously served as Chief Innovation Officer at ICON plc following its acquisition of PRA Health Sciences, where he was Chief Scientific Officer. Over 25 years overseeing drug development and clinical trials at healthcare companies.

Official website: